Vitamin D supplementation, which was initially restricted to the field of bone mineralisation, has recently emerged as a potentially promising treatment in a variety of domains, such as auto-immune diseases, cancer and diabetes. 1 In multiple sclerosis (MS), a beneficial effect of vitamin D has been recently suggested by epidemiological 2 and genetic 3 studies, and related to its general impact on immune function. 4 Are these interesting data sufficient to advise MS or clinically isolated syndrome (CIS) patients to take vitamin D? We believe that conclusive demonstration of the efficacy in MS is still missing, and that the links between 25OH vitamin D intake, vitamin D status, and neurologic outcome remain hypothetical.
Rebuttal
Vitamin D supplementation, which was initially restricted to the field of bone mineralisation, has recently emerged as a potentially promising treatment in a variety of domains, such as auto-immune diseases, cancer and diabetes. 1 In multiple sclerosis (MS), a beneficial effect of vitamin D has been recently suggested by epidemiological 2 and genetic 3 studies, and related to its general impact on immune function. 4 Are these interesting data sufficient to advise MS or clinically isolated syndrome (CIS) patients to take vitamin D? We believe that conclusive demonstration of the efficacy in MS is still missing, and that the links between 25OH vitamin D intake, vitamin D status, and neurologic outcome remain hypothetical.
Has the correlation between vitamin D status and disease activity been demonstrated? YES, but confounding factors cannot be ruled out
In several recent association studies, a significant negative correlation was reported between vitamin D serum level and relapse rate in relapsing-remitting (RR) MS patients, [5] [6] [7] [8] leading to the assumption of a causal relationship between those two variables. In paediatric MS, a retrospective study of 110 patients 9 showed that every 10 ng/ml increase in serum vitamin D3 level was associated with a 34% decrease in the rate of subsequent relapses. Concerning disability level, two cross-sectional studies, including 136 and 267 MS patients, respectively, 10, 5 revealed an inverse association between vitamin D serum level and degree of disability.
These studies, however, failed to consider important confounders such as body mass index, season, vitamin D binding protein concentration and affinity. 11 In addition, the influence of daily life activity on vitamin D level, i.e. that permanently disabled patients usually restrict their outdoor activities, and therefore their exposure to the sun, was not taken into account. Other concerns are the different vitamin D assays currently available, and standardisation is still an unmet need.
Has the impact of vitamin D supplementation on MS outcome been demonstrated? NO
An early publication 12 reported in 1986 that vitamin D supplementation for two years was associated with a 50% decrease in the number of relapses, but this uncontrolled study included only 10 patients. Since then, several randomised phase 2 studies have evaluated the influence of vitamin D supplementation on disease activity. These studies, in which most but not all patients were on immunomodulators, have all been negative concerning clinical endpoints. The study by Kampman et al. 13 of 68 MS patients showed no difference in clinical outcome at 96 weeks. The study reported by Burton et al. 14 of 49 patients treated during one year showed a decrease in the relapse rate in the vitamin D group (-41% vs -17% in the control group), but this trend was not significant. The one-year trial conducted by Shaygannejad et al. of 50 RRMS patients 15 did not show any significant difference in Expanded Disability Status Scale (EDSS) and relapse rates. Although it is important to take into account that these studies differed in the dose of vitamin D used, the study by Stein et al. 16 failed to detect any beneficial effect of high versus low doses of vitamin D supplementation on clinical relapses. These negative results can certainly be related to the small size of these phase 2 studies, not allowing for the detection of a clinical effect. Concerning studies with magnetic resonance imaging (MRI) endpoints, however, one single, double-blind, placebo-controlled, randomised study including 66 MS patients showed a positive impact of vitamin D supplementation, with fewer new T2 lesions and a significantly lower number of T1 enhancing lesions after one year. 17 In contrast, two other controlled studies of 68 and 62 MS patients failed to demonstrate a significant effect on MRI endpoints. 18, 13 
General concerns with studies of vitamin D intake
Controlled phase 3 studies of vitamin D supplementation in MS are needed. These studies, however, will face a general problem shared with studies of vitamin D in other health domains. Indeed, the vitamin D intake in the "placebo" group depends on the patients' daily diet and metabolism. Given the major difficulty of measuring vitamin D content in food, assessment of dietary exposure is a challenge. Moreover, response to supplemental vitamin D is likely to be different depending on diverse population groups, such as women of reproductive age and dark-skinned individuals. These limitations are major pitfalls for creating homogenous trial groups. In this respect, it is striking to see that, even for bone mineral density, no good evidence exists for an effect of supplemental vitamin D, independent of calcium, phosphate and other nutrients. 11 Concerning adverse events, although rare cases of hypercalcaemia have been reported with daily intake of vitamin D and calcium, 19 the safety profile of vitamin D is very good. One has to keep in mind, however, that these safety data derive mostly from short-term studies, and that non-skeletal effects of longterm treatments, such as soft-tissue calcification and aortic calcifications, should be clarified.
Conclusion
Although genetic and epidemiological data are interesting, available evidence supporting vitamin D supplementation in MS is still lacking. We believe that vitamin D supplementation should be proposed, as for any drug-based therapy, only when sufficient evidence of efficacy has been gathered. If all MS patients receive vitamin D because "it might be useful, and it is not harmful", then it will not be possible to demonstrate either efficacy or lack of efficacy. As stated above, however, such late-phase studies face particular methodological challenges. There is a need to improve dietary assessment methods and to take into account key confounders before initiating such late-phase studies.
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